Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24185406 | 0.88 | ALDH1A1 (0.41) | KDM2B | |
| SCHEMBL24185088 | 0.88 | KDM2B (0.30) | KDM2B | |
| SCHEMBL24185410 | 0.88 | ALDH1A1 (0.41) | KDM2B | |
| SCHEMBL24185112 | 0.88 | ALDH1A1 (0.41) | KDM2B | |
| SCHEMBL24185098 | 0.88 | ALDH1A1 (0.41) | KDM2B | |
| SCHEMBL24185093 | 0.88 | ALDH1A1 (0.41) | KDM2B | |
| SCHEMBL24827882 | 0.85 | — | — | |
| SCHEMBL24827879 | 0.85 | — | — | |
| SCHEMBL24827884 | 0.85 | — | — | |
| SCHEMBL22737426 | 0.85 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11834455-B2 | Carm1 inhibitors and uses thereof | Epizyme, Inc. (US) | 2023-12-05 | — | — | US | disclosed |
| US-20230279020-A9 | CARM1 INHIBITORS AND USES THEREOF | Epizyme, Inc. (US) | 2023-09-07 | — | — | US | disclosed |
| US-9856267-B2 | CARM1 inhibitors and uses thereof | Epizyme, Inc. (US) | 2018-01-02 | — | — | US | disclosed |
| US-20170320883-A1 | CARM1 INHIBITORS AND USES THEREOF | Epizyme, Inc. | 2017-11-09 | — | — | US | disclosed |
| US-9738651-B2 | CARM1 inhibitors and uses thereof | Epizyme, Inc. (US) | 2017-08-22 | — | — | US | disclosed |
| US-20160039834-A1 | CARM1 INHIBITORS AND USES THEREOF | Epizyme, Inc. (US) | 2016-02-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230279020-A9 | CARM1 INHIBITORS AND USES THEREOF | CARM1, TIAM1, ADRM1 | KDM2B 872/4885DPP4 4843/4885 |
| US-20170320883-A1 | CARM1 INHIBITORS AND USES THEREOF | CARM1, TIAM1, ADRM1 | KDM2B 869/4885DPP4 4840/4885 |
| US-11834455-B2 | Carm1 inhibitors and uses thereof | CARM1, TIAM1, ADRM1 | KDM2B 869/4885DPP4 4840/4885 |
| US-20160039834-A1 | CARM1 INHIBITORS AND USES THEREOF | CARM1, TIAM1, ADRM1 | KDM2B 946/4885DPP4 4823/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.